ArticleJournal of thoracic disease2025
Efficacy and safety of postoperative adjuvant immunotherapy for esophageal cancer: a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In view of the fact that immune checkpoint inhibitors (ICIs) have shown promise in the treatment of esophageal cancer, but the efficacy and safety of ICIs in the adjuvant treatment after esophageal cancer resection are still not fully understood, this study aimed to evaluate the efficacy and safety of ICIs in the adjuvant treatment after esophageal cancer resection through meta-analysis. Methods: We conducted a meta-analysis using Review Manager 5.4.1, based on published clinical trials, to assess the therapeutic efficacy and safety profile of ICIs in adjuvant therapy following esophagectomy for esophageal cancer. The primary endpoints included disease-free survival (DFS), overall survival (OS), and the incidence of adverse events (AEs). Results: Four randomized controlled trials (RCTs) were included in the analysis. ICIs demonstrated a significant improvement in DFS in the adjuvant setting [hazard ratio (HR) =0.73; 95% confidence interval (CI): 0.60-0.89; P=0.002]. However, no statistically significant difference in OS was observed between the ICI and placebo groups (HR =0.90; 95% CI: 0.76-1.06; P=0.22). Safety analysis revealed that ICI treatment was associated with a higher incidence of rash [odds ratio (OR) =1.69; 95% CI: 1.24-2.32; P=0.001], pruritus (OR =2.22; 95% CI: 1.56-3.14; P<0.001), hypothyroidism (OR =6.03; 95% CI: 3.77-9.63; P<0.001), and hyperthyroidism (OR =5.91; 95% CI: 2.60-13.44; P<0.001). Conclusions: This is the first meta-analysis evaluating the efficacy and safety of ICIs in the adjuvant treatment of esophageal cancer. The findings suggest that ICIs offer a significant improvement in DFS in patients post-esophagectomy, though no substantial improvement in OS was observed. Notably, the incidence of cutaneous reactions, pruritus, and thyroid dysfunction was higher, underscoring the need for vigilant monitoring in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.